Market News & Trends
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in General Anxiety Disorder
Mind Medicine (MindMed) Inc. recently announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD),…
Daré Bioscience Announces Global Licensing Rights to Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
Daré Bioscience, Inc. recently announced it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights…
Immatics Announces First Cancer Patient Treated With Second-Generation ACTengine TCR-T Candidate
Immatics N.V. recently announced the treatment of the first patient in its Phase 1b expansion cohort C (NCT03686124) evaluating IMA203CD8, the company’s second-generation TCR-T monotherapy…
Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the US
Belite Bio, Inc. recently announced it has commenced enrollment for the US Phase 3 clinical trial of LBS-008 in patients with Stargardt Disease (STGD1), a…
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) – Expressing Cancers
Cue Biopharma, Inc. recently announced it has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102, its second clinical drug candidate…
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients With ALS & FTD
Amydis Inc. recently announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant…
AUM Biosciences Receives FDA Orphan Drug Designation for the Treatment of Solid Tumors With the NTRK Fusion Gene
AUM Biosciences recently announced the US FDA has granted Orphan Drug Designation (ODD) to AUM601, a highly selective, oral small molecule that inhibits not only…
Gerresheimer & Zollner Enter Strategic Partnership
Gerresheimer AG and Zollner Elektronik AG are pooling their market-leading pharmaceutical and medical technology expertise under a strategic partnership. Starting immediately, they will offer pharmaceutical,…
Blue Water Vaccines Announces Exploration of its VLP Platform for Use in Monkeypox Vaccine Candidate
Blue Water Vaccines Inc. recently announced the company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion…
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Selective Allosteric TYK2 Inhibitor VTX958
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….